|Bid||15.55 x 1000|
|Ask||15.71 x 1000|
|Day's Range||15.48 - 16.50|
|52 Week Range||7.55 - 29.61|
|Beta (5Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.56|
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -10.53% and 19.57%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's common stock to three newly-hired employees, with a grant date of July 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).